Facebook criticised for 'pseudoscience' ad-targeting category

Facebook: 'pseudoscience' category reportedly contained more than 78 million users
Facebook: 'pseudoscience' category reportedly contained more than 78 million users

Platform has paused availability of some other ad-targeting categories after this was exposed.

Facebook was until last week allowing advertisers to target users that it had identified as interested in "pseudoscience", jarring with the company's actions to curb the spread of Covid-19 misinformation across its platforms.

The social media network removed the category from its ad portal last week following a Markup investigation, which found that interest category reportedly contained more than 78 million users and was actively available during Covid-19.

Permitting advertisers to target users that may be interested in "pseudoscience", while publicly announcing efforts to prevent coronavirus misinformation or conspiracy theories from running on its platforms, appears hypocritical.

Facebook has been removing content with "false claims or conspiracy theories" relating to Covid-19 since January. However, a separate investigation by US non-profit Consumer Reports earlier this month found that ads containing deliberate and dangerous misinformation relating to Covid-19 are slipping through Facebook's review system.

A spokesperson at Facebook told Campaign Asia-Pacific: "We've removed this targeting option to prevent potential abuse in ads."

The spokesperson added that the pseudoscience interest category "should have been removed in a previous review" and that the company will "continue to review our interest categories". It has paused the availability of some of its other interest categories while it evaluates their potential for misuse.

A version of this story first appeared on Campaign Asia-Pacific

Subscribe today for just $116 a year

Get the very latest news and insight from Campaign with unrestricted access to campaignlive.com , plus get exclusive discounts to Campaign events

Become a subscriber


The latest work, news, advice, comment and analysis, sent to you every day

register free